InventisBio Announces Positive Phase 2 Study Results for D-2570 (TYK2 Inhibitor) in Patients with Moderate to Severe Plaque Psoriasis
– D-2570 demonstrates robust efficacy and favorable safety profile, achieving skin clearance comparable to leading biologics –